Time of hope for the eventual elimination of meningococcal strains A, C, Y, and W-135 in the United States

American Family Physician

Volumn 72, Issue 10, 2005, Pages

  Zimmerman, Richard Kent ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Behavioral and Community Health Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

BACTERICIDAL ACTIVITY; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNITY; IMMUNOGENICITY; MEDICAL INFORMATION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PHYSICIAN; REDUCTION; UNITED KINGDOM; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; CHILD; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; UNITED STATES;

EID: 27844572867     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005;72:2049-56.
2. Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1-21.
3. Shepard CW, Ortega-Sanchez IR, Scott RD II, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005;115:1220-32.
4. Centers for Disease Control and Prevention. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June-July 2005. MMWR Dispatch 2005;54:1-3.
5. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-6.